iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

Core Viewpoint - iBio, Inc. has secured $26 million in PIPE financing to advance its preclinical programs and extend its cash runway, while also reporting no revenue for the second quarter of fiscal year 2026, highlighting significant increases in R&D and G&A expenses [1][4][7]. Financial Results - The company reported no revenue for the three months ending December 31, 2025, compared to $0.2 million for the same period in 2024 [4]. - R&D expenses increased to $4.3 million for the three months ending December 31, 2025, from $1.9 million in the same period of 2024, reflecting a rise of approximately $2.4 million [4][6]. - General and Administrative expenses rose to approximately $5.2 million for the three months ending December 31, 2025, up from $2.7 million in the same period of 2024, an increase of $2.5 million primarily due to impairment of intangible assets [7]. Corporate Updates - iBio has advanced its preclinical pipeline programs, including IBIO-610 and IBIO-600, towards human clinical trials, with CMC development and toxicology studies initiated [2]. - The company presented new data on IBIO-610 at various industry conferences, indicating a predicted human half-life of up to 100 days, which supports potential dosing as infrequently as twice per year [5]. - The company aims to commence first human clinical trials for IBIO-610 in early calendar year 2027 and enter Phase 1a clinical trials for IBIO-600 in the first half of calendar year 2026 [5][6]. Cash Position - As of December 31, 2025, iBio held cash, cash equivalents, and investments in debt securities totaling $52.7 million, with the recent PIPE financing extending the cash runway into the third quarter of fiscal year 2028 [8].